RCT | Effectiveness of Etoposide and Cisplatin vs. Irinotecan and Cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system.

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial – JAMA Oncology

Commentary on Twitter

JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM pic.twitter.com/AQT8U4yd3l

— JAMA Oncology (@JAMAOnc) August 18, 2022